Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NIH Agrees To Evaluate Novavax’ Drug For H1n1 Strain
Novavax, and the Division of Microbiology and Infectious Diseases (DMID) have entered into an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against
Novavax, and the Division of Microbiology and Infectious Diseases (DMID) have entered into an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against
Santaris Pharma has announced that the cancer drug EZN-2968, an inhibitor of HIF, is being evaluated in patients with solid tumors and lymphoma. EZN-2968 is well tolerated, and
The Indian medical equipments market is projected at INR57.5 with a growth rate of 23% expected in the coming years. The market for medical supplies and disposables is
These data will be presented on June 6, 2009 at the European Hematology Association’s (EHA) 14th Congress in Berlin, Germany. Researchers analyzed follow up data from patients enrolled
Abbott and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott’s Trilipix (fenofibric acid). Its a medication to be used alone or
Novartis has announced that the Novartis Vaccines Institute for Global Health has been awarded a grant from the Wellcome Trust to develop a bivalent vaccine for typhoid fever.
Anadys has declared a strategic restructuring to focus its operations on the development of Ana598, in particular a proposed Phase II study in hepatitis C patients of Ana598
AVI BioPharma and Charley’s Fund, a not for profit organization, have amended their existing sponsored research agreement to provide for an additional $3 million in sponsored research funds.
Acces has declared that new Thiarabine preclinical efficacy data will shortly be published, demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either
Abbott and AstraZeneca have announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA). It is for an investigational compound for